Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) activates NF-kB signaling pathways through the two C-terminal regions, CTAR1 and CTAR2. BS69 has previously been shown to be involved in LMP1-induced c-Jun N-terminal kinase activation through CTAR2 by interacting with tumor necrosis factor (TNFR) receptorassociated factor 6. In the present study, our experiments manipulating of BS69 expression clearly indicated that BS69 negatively regulated LMP1-mediated NF-kB activation including up-regulated IL-6 mRNA expression and IkB degradation. For the mechanisms, our immunoprecipitation experiments proposed that BS69 decreased complex formation between LMP1 and TNFR-associated death domain protein (TRADD).
Introduction
Epstein-Barr virus (EBV) is linked to the development of multiple malignancies, including post-transplant lymphoma, Hodgkin disease, and nasopharyngeal carcinoma.
EBV-encoded latent membrane protein 1 (LMP1) is expressed in many EBV-associated tumor cells and is responsible for most of the altered cellular growth properties.
Structurally, LMP1 is an integral membrane protein of 386 amino acids (aa) that consists of a short cytoplasmic N-terminal domain (aa , six transmembrane domains (aa ) and a long cytoplasmic C-terminal tail (aa 187-386) [1, 2, 3] . The cytoplasmic C-terminal tail contains two C-terminal activation regions (CTARs), CTAR1 and CTAR2, which are required for LMP1-transduced signaling through tumor necrosis factor receptor (TNFR)-associated factors (TRAFs) [1, 4] . CTAR1 contains a consensus TRAF-binding motif (PXQXT), and can bind to TRAFs 1, 2, 3 and 5 [1, [5] [6] [7] [8] .
CTAR2 interacts with TNFR-associated death domain protein (TRADD), receptorinteracting protein (RIP) [9, 10] and BS69 [11] . Signals through these two domains induce p100 and p105 NF-kB precursors and generate p52 and p50 subunits, respectively [12, 13] , indicating that LMP1 is involved in both canonical and noncanonical activation of NF-kB pathway. Binding of LMP1 to TRAFs and TRADD also initiates the formation of a signaling complex that leads to activation of mitogenactivated protein kinase, p38 [14] . In addition, activation of c-Jun N-terminal kinase (JNK) by LMP1 is mediated through CTAR1 and CTAR2 [15] .
BS69, a multidomain cellular protein containing PHD, Bromo, PWWP and MYND domains, was originally identified as an adenovirus E1A-binding protein that inhibits the transactivation function of E1A [16] . Furthermore, the C-terminal MYND domain of BS69 was shown to bind to the PXLXP motif existing on E1A, the EBV-encoded EBNA2 and a Myc-related cellular protein MGA [17] . It has recently been shown that BS69 interacts with EBV-encoded LMP1, through its MYND domain and acts as a scaffold protein in the LMP1-mediated JNK pathway [11] by interacting with TRAF6.
However, the involvement of BS69 in LMP1-mediated NF-kB activation is still undetermined. Here, we investigated the influence of BS69 on LMP1-mediated NF-kB activation.
Our main finding was that BS69 could downregulate LMP1-mediated NF-kB activation including LMP1-induced interleukin (IL)-6 mRNA expression and IkB degradation. We further found that BS69 decreases complex formation between LMP1 and TRADD. Therefore, BS69 is likely to act as an endogenous negative regulator of LMP1-mediated NF-kB activation by displacing TRADD from LMP1.
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Materials and methods
Reagents and antibodies
Recombinant human TNF-a was kindly provided from Dainippon Sumitomo Pharma (Osaka, Japan). Expression vectors for BS69, BRAM1, TRADD and NF-kB-LUC were kindly provided by H. Shibuya (Tokyo Medical and Dental University, Tokyo, Japan), N. Inohara (University of Michigan Medical School, Ann Arbor, MI) and T. Fujita (Kyoto University, Kyoto, Japan) [18] [19] [20] . Epitope-tagged STAP-2 and epitope-tagged LMP1 constructs were described previously [19, 20] The following primary antibodies were obtained commercially: anti-TRADD, anti-NF-kB p65 and anti-Myc antibodies (Santa Cruz Biotechnology, Santa Cruz, CA); anti-FLAG mAb (M2) and anti-HA antibody (Sigma-Aldrich, St. Louis, MO); anti-IkB antibody, anti-phospho-JNK (pJNK) and anti-JNK (Cell Signaling Technology, Beverly, MA); and anti-actin mAb (Chemicon International, Temecula, CA). An anti-LMP1 mAb (S12) was prepared as described previously [19] . 
Cell culture and transfection
A human cervix carcinoma cell line (HeLa), human embryonic kidney carcinoma cell line (293T) and human hepatoma cell line (Hep3B) were maintained in DMEM containing 10% FCS. HeLa/pcDNA3 and HeLa/STAP-2 transfectants were prepared as described previously [19] . HeLa cells were transfected using jetPEI (PolyPlustransfection, Strasbourg, France) according to the manufacturer's instructions. 293T cells were transfected using a standard calcium precipitation protocol [21] .
Transfection of small-interfering RNAs (siRNAs) and luciferase assays
The siRNAs targeting human BS69 (#1 and #2) used in this study were as follows: Carlsbad, CA) mixture at 37°C for 4 h, followed by the addition of fresh medium containing 10% FCS. HeLa cells were further transfected with or without NF-kB-LUC with or without LMP1 using jetPEI as described in the section above. At 24 h after transfection, the cells were harvested and assayed for their luciferase activities using a Dual-Luciferase Reporter Assay System (Promega, Madison, WI) according to the manufacturer's instructions. 293T cells were transfected as described in the section above. The cells were harvested at 36 h after transfection, lysed in 50 ml of Reporter Lysis Buffer (Promega) and assayed for their luciferase and b-galactosidase activities according to the manufacturer's instructions. Three or more independent experiments were carried out for each assay.
3. Immunoprecipitation and immunoblotting
Immunoprecipitation and western blotting assays were performed as described previously [21] . The immunoprecipitates from cell lysates were resolved by SDS-PAGE and transferred to PVDF membranes (PerkinElmer, Boston, MA). The membranes were then immunoblotted with the different primary antibodies. Immunoreactive proteins were visualized using an enhanced chemiluminescence detection system (Millipore, Bedford, MA).
4. RNA isolation, RT-PCR and quantitative real-time PCR
After cell harvesting, total RNA samples were extracted using Iso-Gen (Nippon Gene, Tokyo, Japan) and subjected to RT-PCR using an RT-PCR High -Plus-Kit (TOYOBO, Tokyo, Japan) [19] . Primers used for RT-PCR were: BS69: 5'-GGATATTGGTTGCCAGGA GA-3' (sense), 5'-GTGCCCATCTCCTGTTTGTT-3' (antisense). Quantitative real-time PCR analyses for IL-6, BS69 and control G3PDH mRNA transcripts were carried out using Assays-on-Demand TM gene-specific fluorescently-labeled TaqMan MGB probes in an ABI Prism 7000 sequence detection system (Applied Biosystems, Foster City, CA).
Indirect immunofluorescence microscopy
To analyze the subcellular localization of LMP1 and BS69 proteins, FLAG-tagged LMP1 and HA-tagged BS69 were transiently transfected into HeLa cells by Jet-PEI.
Immunofluorescence stainings were performed as described [19] . The following primary antibodies were used: mouse anti-HA and rabbit anti-FLAG antibodies. Two secondary antibodies were used: rhodamine-conjugated anti-mouse IgG or fluorescein isothiocyanate (FITC)-conjugated anti-rabbit IgG (Chemicon). DNA was visualized with DAPI (Wako Chemicals, Osaka, Japan) staining. Confocal laser scanning microscopy was performed with a LSM510 microscope (Carl Zeiss, Thornwood, NY) with an Apochromat x63/1.4 oil immersion objective, using excitation wavelengths of 9
Results and discussion
1. BS69 negatively regulates LMP1-induced NF-kB activation
We previously showed that STAP-2 suppressed LMP1-induced NF-kB activation and that overexpression of BS69 failed to affect the negative effects of STAP-2 [19] .
However, information that BS69 can bind to the cytoplasmic C-terminal domain of LMP1 [11] let us investigate the individual effects of BS69 on LMP1-induced NF-kB activation using transient reporter assays with NF-kB-LUC. NF-kB-LUC activities were markedly induced by the expression of LMP1 in HeLa and 293T cells (Fig. 1) .
Importantly, the LMP1-induced NF-kB-LUC activities were significantly reduced by co-expression of BS69 in a dose-dependent manner, suggesting that BS69 negatively regulates LMP1-induced NF-kB activation. Recently, an alternatively spliced variant of BS69, BRAM1has also been shown to interact with the C-terminal domain of LMP1 and influence LMP1-mediated NF-kB activation [22] . BRAM1 protein shares the Cterminal 186 amino acids including a MYND domain with BS69 [18] . Thus, we examined the effect of BRAM1 on LMP1-induced NF-kB activation in the same situation. As shown in Fig, 1B , BRAM1 as well as BS69 decreased LMP1-induced NFkB activation, and similar amounts of both proteins were required for this suppressive effect. To exclude the possibility that the suppression of NF-kB activation is a result of promoter interference, the expression vector carrying TRAF1 cDNA was transfected into 293T cells, and LMP1-induced NF-kB activation was analyzed in those cells. As expected, overexpression of TRAF1 failed to influence NF-kB-LUC activity induced by LMP1 (Fig. 1C) . We then tested the effect of ectopic exprerssion of BS69 or BRAM1 on NF-kB activation induced by TNF-a, which uses different signaling pathway from LMP1. As shown in Fig, 1D , neither BRAM1 nor BS69 overexpression reduced TNFa-induced NF-kB-LUC activity in HeLa cells. Therefore, overexpression of BS69 negatively regulated LMP1-induced NF-kB activation. BS69 is shown to act as a scaffold protein in the LMP1-mediated JNK pathway [11] . We also examined the effect of BS69 and BRAM1 on LMP1-induced JNK activation using a phospho-specific anti-JNK antibody. As shown in Fig. 1E , ectopic expression of BS69 enhanced LMP1-induced JNK activation as previously reported [11] . However, BRAM1 expression had no effect on LMP1-induced JNK activation. Therefore, BS69 but not BRAM1 positively regulates LMP1-mediated JNK pathway.
To further explore whether BS69 represses LMP1-induced NF-kB activation, we used siRNAs to reduce endogenous expression of BS69 in HeLa cells (Fig. 2) . HeLa cells were transfected with specific siRNAs for BS69 (#1 and #2) or a control siRNA. Total RNA isolated from the transfected cells was subjected to RT-PCR and quantitative realtime PCR analysis, which confirmed a reduction of BS69 mRNA expression. We then determined the effects of BS69 siRNAs on LMP1-induced NF-kB activation in HeLa cells. As shown in Fig. 2B , siRNA-mediated reduced expression of BS69 resulted in a significant enhancement of LMP1-induced NF-kB-LUC activities in these cells. 293T cells express adenovirus E1A, and HeLa cells are known to express human papillomavirus E7 oncoprotein that is structurally and functionally related to E1A and may also bind BS69 [23] . Because the presence of these virus-related oncoprotein may affect the effect of BS69, we confirmed direct effect of BS69 siRNAs on LMP1-induced NF-kB activation in E7 negative human hepatoma Hep3B cells. As shown in (Fig. 2D) . To further assess the effects of BS69 on LMP1-induced canonical NF-kB activation, we examined the effects of BS69 siRNA on LMP1-induced IkBa degradation. The BS69 siRNA-mediated reduction of BS69 markedly enhanced LMP1-induced IkBa degradation in HeLa cells (Fig. 2E) . In addition, IL-6 mRNA expression and IkBa degradation were slightly enhanced in the BS69 siRNA-treated HeLa cells even in the absence of LMP1-expression. There might be the possibility that endogenous BS69 regulates basal NF-kB activation by interacting with potent NF-kB activators such as TRAF6, because BS69 has been shown to bind to TRAF6 [11] . At the present time, we do not know the mechanisms of regulation of basal NF-kB activation by BS69. Further detailed study will be required to clarify this issue. Taking these results together, BS69 acts as a negative regulator in LMP1-mediated NF-kB activation.
2. Intracellular localization of BS69, LMP1, and NF-kB
We examined cellular co-localization of BS69 and LMP1 in vivo using confocal microscopy. HeLa cells were transfected with FLAG-tagged LMP1 and HA-tagged BS69 constructs. BS69 was mainly localized in the nucleus (Fig. 3A) . However, when co-expressed with LMP1, BS69 protein was in part concentrated in punctate vesicularlike and perinuclear structures where LMP1 was also mainly localized, demonstrating 13 that LMP1 co-localized with BS69 in vivo (Fig.3B) . We further examined whether expression of BS69 has any effect of cellular localization of NF-kB p65 in vivo. As shown in Fig. 3C , even in the presence of BS69, NF-kB p65 protein was mainly localized in the cytoplasm. Co-localization of BS69 with NF-kB p65 and a significant nuclear translocation of NF-kB p65 were not observed, suggesting that BS69 has no direct effect on NF-kB p65 in the regulation of NF-kB signaling.
BS69 regulates LMP1-induced NF-kB activation by displacing TRADD from
LMP1
In a previous study, BS69 has been demonstrated to interact with the CTAR2 domain of LMP1 and activate the JNK pathway by interacting with TRAF6 [11] . To further examine the molecular mechanisms of BS69-mediated suppression of NF-kB activation, we tested whether BS69 associates with other downstream molecules through the CTAR2 domain for LMP1-mediated NF-kB activation such as TRADD and STAP-2.
We have demonstrated that siRNA-mediated reduction of TRADD results in a significant decrease of LMP1-mediated NF-kB-LUC activities in HeLa cells, whereas siRNA-mediated reduction of STAP-2 revealed a significant enhancement of NF-kB activation in HeLa cells [19] . To delineate the molecular interactions between BS69 and these molecules, we first examined whether BS69 directly interacts with TRADD or STAP-2 in vivo. 293T cells were transfected with either HA-tagged TRADD or Myctagged STAP-2 together with HA-tagged BS69. Western blot analysis of the associated proteins with an anti-HA or anti-Myc antibody revealed that BS69 did not interact with either STAP-2 or TRADD (Fig.4A & 4C) . BRAM1 also failed to interact with STAP-2 or TRADD (Fig.4B & 4D) . We previously demonstrated that STAP-2 displaces TRADD from LMP1 and inhibits LMP1-mediated NF-kB activation. We then examined the effects of BS69 or BRAM1on the interactions between LMP1 and TRADD. Interestingly, TRADD failed to bind to LMP1 in the presence of BS69 or BRAM1 (Fig. 4E & 4F) , indicating that BS69 and BRAM1 inhibit physical interactions between LMP1 and TRADD. These results suggest that BS69 decreases the formation of LMP1/TRADD complexes through the C-terminal region encoding BRAM1.
4. Concluding remarks
We here demonstrate that BS69 negatively regulates LMP1-mediated NF-kB activation by displacing TRADD from LMP1. Previous studies demonstrated that BS69 acts as a transcription repressor in association with a variety of transcription factors such as c-Myb, B-Myb, Ets2 and MGA [24] [25] [26] [27] . BS69 has also been shown to repress transcription by recruiting N-CoR [28] . Furthermore, BS69 has also been shown to associate with mitotic chromosomes and interacts with Brg1 (the catalytic subunit of the mammalian SWI/SNF complex), indicating another role of BS69 in chromatin remodeling [29] . BS69 was originally identified as an adenovirus E1A-binding protein that inhibits the transactivation function of E1A [16] by interacting with the PXLXP motif present in E1A. These functions may be coincident with the fact that BS69 negatively regulates EBV LMP1-mediated NF-kB and JNK signaling pathways. HA-tagged LMP1 (3 ng) and NF-kB-LUC (100 ng) using jetPEI. At 48 h after through CTAR2. BS69 and its alternative spliced form, BRAM1 regulate CTAR2-mediated canonical NF-kB activation by displacing TRADD from LMP1. LMP1-induced JNK activation is mediated by BS69 and TRAF6. BS69 also interacts with EBV-encoded latency nuclear protein EBNA2.
